Inhibrx Biosciences vs Cartesian Therapeutics
Cartesian Therapeutics is the larger business, with $2.8m of revenue in fiscal 2025 against $1.3m for Inhibrx Biosciences (2.2 times as much). Inhibrx Biosciences grew faster (550.0% against -92.8%). Cartesian Therapeutics kept more of each dollar of sales as profit: a net margin of -4658.6% against -10773.5%.
| Latest fiscal year | Inhibrx BiosciencesINBX, 2025 | Cartesian TherapeuticsRNAC, 2025 |
|---|---|---|
| Revenue | $1.3m | $2.8m |
| Revenue growth | 550.0% | -92.8% |
| Net income | −$140m | −$130m |
| Operating margin | -10386.5% | -5127.1% |
| Net margin | -10773.5% | -4658.6% |
| Return on equity | -197.8% | — |
| Free cash flow | −$130m | −$79.4m |
| Cash | $124m | $125m |
| Total debt | $101m | $0 |
| Debt to equity | 1258.1% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 110 | 75 |
| Market value | $1.21bn | $193m |
| Price vs our value range | — | — |
| Moat score | — | 9 (Weak) |
| Insider trades, 12 months | 19 buys, 5 sales | 1 buys, 3 sales |